After $ALNY last month, thought I could walk on water, then $OPHT + $SRPT. Always stay humble+be thankful for all other biolandmines avoided
No Wells Fargo! Hurrah! $VRX $AGN $MYL $MRK $teva $JNJ $AZN $BMY $AAPL $WFB $AMGN $SRPT $PRGO $tst $eXel $GILD… https://t.co/pv3PG4sSYc
$CRM, $PANW, $TASR, $AMBA, $WTW, $SRPT, $ACAD, $ETSY, $VEEV, $ROST, $CBI, $JAZZ, $LOGM, $AMC https://t.co/6LCVAohiF6
$ACAD 2017 revenue $85 M, mcap : ~$5B, $SRPT mcap of ~$1.5B for revenue of $85 M...
RT @RNAiAnalyst: To read it as $80M and not >80M never made much sense in light of this Q numbers, but people jump at (any) number they are…
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
$SRPT "..guidance to EXCEED $80M for the year". Did everyone miss "exceed"? Another short driven lie to hide this fact.
To read it as $80M and not >80M never made much sense in light of this Q numbers, but people jump at (any) number t… https://t.co/bH70mjJwX9
RT @theflynews: On The Fly: After Hours Movers $BGFV $DAR $WTW $DPLO $LOGM $BLDR $TASR $DVAX $TIME $LXRX $WLH $PANW $ENPH $SRPT… https://t.…
$srpt overreaction... this is going to fly nect days/weeeks.. way ubdervaluee
When is eu approval .. anyone ? $srpt
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
RT @DrSManian: Cowen $SRPT
ALL Tier1 centers (50% of market) & all but 1 Tier2 centers (30% of market)" have submitted start forms https:/…
No surprise here: always knew etep's mkt <<< than sell-siders estimates, wud have efficacy &reimbursement issue… https://t.co/HjISB0IDoo
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
RT @darock2399: On watch $WTW $ETSY $SRPT $HK & earning tomorrow before open $AKRX $BBY $FOLD $KERX watching gaps
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
RT @DrSManian: "We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
@pawcio2009 @wz2013 @DrSManian Ed/ $srpt 180 deg different approach from the $kite ceo today. Lets see who raises first....
@t_rupp $srpt have to see if there are more 13G's filed in next several days. There have been 6 in last month. https://t.co/I64bDSbXRB
RT @DrSManian: "We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
RT @theflynews: On The Fly: After Hours Movers $BGFV $DAR $WTW $DPLO $LOGM $BLDR $TASR $DVAX $TIME $LXRX $WLH $PANW $ENPH $SRPT… https://t.…
RT @DrSManian: Cowen $SRPT
ALL Tier1 centers (50% of market) & all but 1 Tier2 centers (30% of market)" have submitted start forms https:/…
RT @DrSManian: "We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
@DrSManian $srpt inexperienced CEO, who guides to the absolute worst?
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
Cowen $SRPT
ALL Tier1 centers (50% of market) & all but 1 Tier2 centers (30% of market)" have submitted start forms https://t.co/d83xFBVNTG
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
RT @DrSManian: "We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
RT @DrSManian: "We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
"We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
RT @BiotechHack: $SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
$SRPT Cowen saying after talking w management $80m a worst case scenario https://t.co/nw58rpeO4t
$SRPT Boss informed me my salary 4 2017 will b Greater than $1. But @BrianSkorney called me up 2 remind "Hey at least u know ur not fired"
RT @cool_eran: @Quarry_Rock $SRPT should rise 10% on trump's $FOLD mension. Year guidance a non issue here, though quite stupid. Min 80 mil…
RT @cool_eran: @Quarry_Rock $SRPT should rise 10% on trump's $FOLD mension. Year guidance a non issue here, though quite stupid. Min 80 mil…
@Pharmdca $SRPT maybe a little sympathy bounce?
@megtirrell Not me, too busy ciphering where I want to buy $SRPT :)
@Quarry_Rock $SRPT should rise 10% on trump's $FOLD mension. Year guidance a non issue here, though quite stupid. Min 80 mil$=fast uptake.
$SRPT had $329.3 million in cash
$SRPT LOLOLOLOL
Biotech $SRPT Crushed On\u2026 $SRPT https://t.co/7vGSMVQiED
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
Biotech $SRPT Crushed On Bigger Loss, See Buy Levels Here... https://t.co/SrKOiKuq3H
RT @adamfeuerstein: $SRPT if you weed out the outlier (ridiculous) sell-side forecasts, “consensus” 2017 sales estimate is $100-110 million…
$SRPT this is my cash cow look like her milk is drying up." I am neutral on $SRPT
RT @QTRResearch: Last time $SRPT was $26 the drug wasn't even approved & 2017 looked like $0 in revenue. Now you're going to sell it on an…
Go long $SRPT ....
#POTUS
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
On watch $WTW $ETSY $SRPT $HK & earning tomorrow before open $AKRX $BBY $FOLD $KERX watching gaps
Not buying $SRPT until Ed buys again.
RT @theflynews: On The Fly: After Hours Movers $BGFV $DAR $WTW $DPLO $LOGM $BLDR $TASR $DVAX $TIME $LXRX $WLH $PANW $ENPH $SRPT… https://t.…
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @DrSManian: $SRPT Brian Skorney with an early defense.
"Market has completely misread this guidance" https://t.co/x7B8jYHsQe
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @IonisDisrupts: $SRPT Is @TheStreet @AdamFuerstein still pumping this one? Not good! #biotech
$SRPT Is @TheStreet @AdamFuerstein still pumping this one? Not good! #biotech
3-1 Watchlist
$PBMD $VRAY $ARWR $SGY $DVAX $SKLN $HTGM $SRPT
$SRPT #nailedit ...and by nailed it I mean my nuts to my wallet.
I get a kick out of $SRPT, in the balls. #notfatal
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
$SRPT:
Sarepta predicts slower sales of Duchenne drug than many …:
https://t.co/RnP8NsXUfO
$srpt holding though today's earnings with a gain be like https://t.co/Bq4QqXsPbG
$SRPT target buyout low $40s
If any fiber of your being believes in $SRPT....what an opportunity tomorrow brings.
What's funny how market is treating $SRPT like a retailer. May be the name sounds like a clothing store?
$SRPT (IV30) is 78.8, and has moved +3.4% from yesterday. Its IV Ranking is 0.36, which is considered Subdued. https://t.co/2p1q80G4Qf
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @theflynews: On The Fly: After Hours Movers $BGFV $DAR $WTW $DPLO $LOGM $BLDR $TASR $DVAX $TIME $LXRX $WLH $PANW $ENPH $SRPT… https://t.…
@Pharmdca @DrSManian think we see more downside then I assume? Ah lows won't hold? $srpt
RT @AndyBiotech: $SRPT guides 1Q17 revenue of $13~15M and FY17 net revenue >$80M
RT @adamfeuerstein: $SRPT if you weed out the outlier (ridiculous) sell-side forecasts, “consensus” 2017 sales estimate is $100-110 million…
$SRPT Brian Skorney with an early defense.
"Market has completely misread this guidance" https://t.co/x7B8jYHsQe
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
@DrSManian $srpt /Ed imo know what they r doing. Either they intended to lower expectations or they are helping out a whale like Cohen etc
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
$srpt Fact is that there was a lot to be positive about. Insurers clearly coming around. Sales ramping. Europe near-certain approval.
@DrSManian will be watching another dip in $srpt to low 20's and planning to add big than. Panic creates opportunities (rlyp was big for me)
RT @adamfeuerstein: $SRPT if you weed out the outlier (ridiculous) sell-side forecasts, “consensus” 2017 sales estimate is $100-110 million…
@behindthadeuce $srpt matched consensus 1st Q guidance of ~$15M so they r still on pace 2 match full2017 consensus guidance.
Smart thing for $SRPT to do would've been simply reiterate JPM patient numbers & talk $$ on Q2 CC. Don't think they… https://t.co/PjzWSgtvtc
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
$DVAX $LXRX $LMT $PANW $PCLN $IWM $SRPT Market recap 2.28.17 https://t.co/D7mufNGTrx
RT @markflowchatter: Skorney-Baird "we think the market has completely misread this
guidance, interpreting it as an expectation rather than…
RT @DrSManian: 250 pts exactly inline with JPM guidance & sent $SRPT soaring from 29 to 38.
Now simple math of that 250 estim gets 32 to 26…
RT @DrSManian: 250 pts exactly inline with JPM guidance & sent $SRPT soaring from 29 to 38.
Now simple math of that 250 estim gets 32 to 26…
250 pts exactly inline with JPM guidance & sent $SRPT soaring from 29 to 38.
Now simple math of that 250 estim gets… https://t.co/qab40BKeMz
RT @DrSManian: My thoughts exactly
250 patients roughly gets you 80-100M$ by EOY1 & $SRPT guiding to low end of that range.
A/H panic hairc…
RT @DrSManian: My thoughts exactly
250 patients roughly gets you 80-100M$ by EOY1 & $SRPT guiding to low end of that range.
A/H panic hairc…
My thoughts exactly
250 patients roughly gets you 80-100M$ by EOY1 & $SRPT guiding to low end of that range.
A/H pa… https://t.co/GkirLBOw1Q
@Val_Invest_12 unfortunately i don't think shareholders will continue to tolerate the ambiguity the current $SRPT regime is notorious for
@given2tweet $SRPT u obsessed 4 years..claimed done when u exited. yet.still in ur stream. When Nora gets hitched at 16 in WV, still $SRPT?
PM #Earnings $CRM $PANW $TASR $AMBA $WTW $SRPT $ACAD $ETSY $VEEV $ROST $CBI $JAZZ $LOGM $AMC https://t.co/7jYKkucO3M https://t.co/Q27YvVYOSx
.@dr_mysterio acquiring $SRPT would not be for Exondys only, but about DMD dominance. $BMRN
#Sarepta predicts slower sales of Duchenne drug than many investors hoped. Read more: https://t.co/YYnmmqjlt1 $SRPT
@ChazMac09 their second full Q of rev should be $2mill higher than $acad yet $srpt mc 1/3rd
$LIFE $BASI $FNHI $NFEC $ETRM $BSTG $KND $EYEG $TTD $BCRX $MBOT $SYRX $GRAM $EVOK $PBMD $SRPT $GEGI #stocks… https://t.co/e9E8g6fjLo
Sarepta Therapeutics, Inc. $SRPT Announces Earnings Results https://t.co/xX1OU08cRz
$SRPT Setting Expectations to Outperform. AH OverRxn. Does it work? Y X51, 45, 53D Approved? Y Sales^? Y Pipeline? Y Easier FDA? Big Maybe??
$SRPT ultimately, the financial success won't come down on precise launch numbers, but whether exon skipping proven to work for DMD.
RT @DrSManian: "We see this worst case scenario as highly unlikely"
"Maintain our 96MM/FY17 estimate"
Cowen
$SRPT https://t.co/CWZGkUZjdz
$SRPT "At this stage of the launch, there are too many variables in flux for us to provide detailed forward looking guidance for the year"
$ACAD 2017 revenue $85 M, mcap : ~$5B, $SRPT mcap of ~$1.5B for revenue of $85 M...
Will say tho w/ a streamlined FDA towards easier approvals, likely $SRPT additional exon skipping sees approval based off rarity & safety
Takeaways from $SRPT conf call: Progress on Exons 45/53, PPMO, innovative trials. Est 2017 sales >$80 mill. Readying Europe Exondys 51
$SRPT running numbers, $80m guide is the number they hit if they add ZERO new patients past Q1... hence 'will EXCEED $80m'.. free gift here
$SRPT will be $103 even after results
$SRPT They literally said this on TONIGHT'S call. Let that sink in. https://t.co/qoVvPf6SG3
PIPER reducing $SRPT price target to $43 from $68 due to lower Exondys51 sales forecast @_B_I_O_T_E_C_H_ https://t.co/ToTNRrSIuV
PIPER reducing $SRPT price target to $43 from $68
due to lower Exondys51 sales forecast
After Hours Movers $BGFV $DAR $WTW $DPLO $LOGM $BLDR $TASR $DVAX $TIME $LXRX $WLH $PANW $ENPH $SRPT
$SPY $WTW $LOGM $SRPT $EVHC $BGFV https://t.co/WLgbe32cnM
Why SRPT Is DOWN In After Hours Trading Sarepta Therapeutics Earnings Results https://t.co/h7Y8EUQAnS $SRPT
Most searched small-cap stocks, Tue Feb 28th - $SRPT $RH $MEDP $JASO $GAIA $TTMI $AAOI $HL $LGCY - More: https://t.co/1znvSOIJVT - #smallcap